Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged Rituxan
When did Mylan agree to launch its Herceptin biosimilar?

Mylan’s biosimilar for Herceptin® has FDA approval since December 2017.  Several months earlier, in March 2017, Mylan reached a global settlement with Roche and Genentech regarding their patents covering the drug.  The terms of the settlement have not been made public, which raises the question – when did Mylan agree to launch? 

Read More
Markman AdvisorsMylan, Herceptin, Rituxan, FDA, Roche, Genentech, Inter Partes Review, IPR, chemotherapy, biosimilar, Humira, BPCIA, Celltrion, Teva, Amgen, Samsung, Pfizer Comment
Roche prevails on two IPR challenges to Herceptin patents—does it matter?

We previously wrote about Roche’s encroaching biosimilars for Ritxuan®, Herceptin®, and Avastin®.  This week, Roche prevailed on two IPRs covering patents for Herceptin®, but lost a third IPR covering another patent for the same drug. What does this mean? 

Read More
Markman AdvisorsRoche, Rituxan, Herceptin, Avastin, Celltrion, Amgen, Samsung Bioepis, Mylan, $PFE, $AMGN, $MYL, BPCIA, Zachary Silbersher, Silbersher, biosimilar, patent, IPR, Inter Partes Review, aBLAComment
Did AbbVie create a wrongful “patent thicket” around Humira®?

​​​​​​​Boehringer Ingelheim has claimed that AbbVie wrongfully created a “patent thicket” around Humira®, and it is delaying biosimilar competition.  While that defense is unique, and may be hard to prove on its face, the FDA appears to agree with Boehringer.  Did AbbVie create a wrongful “patent thicket” around Humira®?

Read More
Markman AdvisorsAbbVie, ​​​​​​​Boehringer Ingelheim, Amgen, Samsung Bioepis, Mylan, Sandoz, Novartis, Humira, adalimumab, biosimilar, Biosimilars Action Plan, biologic, FDA, Gottlieb, Roche, Avastin, Herceptin, Rituxan, Zachary Silbersher, Silbersher Comment
How long can Roche keep back biosimilars for Avastin®, Herceptin® or Rituxan®?

The biosimilars are biting.  And they are biting at three big biologics distributed by Roche through its biotech subsidiary, Genentech.  Roche currently faces pending biosimilar competition against Avastin® (bevacizumab), Roche’s biggest selling cancer drug, Herceptin® (trastuzmab), Roche’s breast-cancer drug, and Rituxan® (rituximab), Roche’s immunotherapy drug.  All three drugs are involved in patent litigations. How long will these cases last? And how long can Roche keep the biosimilars out?

Read More
Markman AdvisorsRoche, Genentech, Avastin, Herceptin, Rituxan, Celltrion, Teva, Amgen, Sandoz, Novartis, Pfizer, $TEVA, $NVS, $AMGN, $PFE, patent, IPR, biosimilar, BPCIA, biologic, biologics, Hatch-Waxman, Zachary Silbersher, Silbersher, FDA, Enbrel, AbbVie, HumiraComment